Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
Lowering low-density lipoprotein cholesterol plays an important role in therapeutic strategies designed to reduce cardiovascular risk. However, the residual clinical risk in statin trials suggests that additional therapies will be required to achieve more effective prevention of cardiovascular disease. The high prevalence of hypertriglyceridemia and low levels of high-density lipoprotein cholesterol in diabetes presents further targets for the development of new cardioprotective therapies.
Nicholls
Stephen J
SJ
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. nichols1@ccf.org
Lundman
Pia
P
Tardif
Jean-Claude
JC
D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D048909:Diabetes Complications / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D014280:Triglycerides